[HTML][HTML] Radiolabeled somatostatin analogues for diagnosis and treatment of neuroendocrine tumors
V Ambrosini, L Zanoni, A Filice, G Lamberti, G Argalia… - Cancers, 2022 - mdpi.com
Simple Summary Neuroendocrine neoplasms (NENs) are rare and heterogeneous tumors,
presenting in often challenging clinical scenarios, and require multidisciplinary discussion …
presenting in often challenging clinical scenarios, and require multidisciplinary discussion …
[HTML][HTML] Neuroendocrine Tumors: Genomics and Molecular Biomarkers with a Focus on Metastatic Disease
ES Alexander, E Ziv - Cancers, 2023 - mdpi.com
Simple Summary Liver metastases secondary to neuroendocrine tumors (NETs) are
common at the time of diagnosis and are associated with worse quality of life and overall …
common at the time of diagnosis and are associated with worse quality of life and overall …
[HTML][HTML] Dual [68Ga]DOTATATE and [18F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the …
DL Chan, AR Hayes, I Karfis, A Conner… - British Journal of …, 2023 - nature.com
Abstract Background Gastroenteropancreatic neuroendocrine neoplasms (GEPNENs) are
heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts …
heterogeneous in clinical course, biology, and outcomes. The NETPET score predicts …
Prognostic value of 18F-FDG PET/CT in a large cohort of patients with advanced metastatic neuroendocrine neoplasms treated with peptide receptor radionuclide …
J Zhang, Q Liu, A Singh, C Schuchardt… - Journal of Nuclear …, 2020 - Soc Nuclear Med
The objective of this retrospective study was to determine the role of 18F-FDG PET/CT in a
large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were …
large cohort of 495 patients with metastatic neuroendocrine neoplasms (NENs) who were …
The combined interpretation of 68Ga-DOTATATE PET/CT and 18F-FDG PET/CT in metastatic gastroenteropancreatic neuroendocrine tumors: a classification system …
AR Hayes, LF O'Mahony, AM Quigley… - Clinical Nuclear …, 2022 - journals.lww.com
Purpose Gastroenteropancreatic neuroendocrine neoplasms (GEP NEN) are widely
heterogeneous in their biological behavior, and predicting prognosis and optimal treatment …
heterogeneous in their biological behavior, and predicting prognosis and optimal treatment …
Long‐term survival and toxicity in patients with neuroendocrine tumors treated with 177Lu‐octreotate peptide radionuclide therapy
KR Kennedy, JH Turner, WBG MacDonald… - Cancer, 2022 - Wiley Online Library
Background Peptide receptor radionuclide therapy (PRRT) has shown favorable results in
neuroendocrine tumors (NETs). Long‐term safety and efficacy data for 177Lu‐octreotate …
neuroendocrine tumors (NETs). Long‐term safety and efficacy data for 177Lu‐octreotate …
Long-term outcome of indigenous 177Lu-DOTATATE PRRT in patients with Metastatic Advanced Neuroendocrine Tumours: a single institutional observation in a …
K Sitani, RV Parghane, S Talole… - The British journal of …, 2021 - academic.oup.com
Objectives: Assessment of long-term outcome and toxicity of indigenous 177Lu-DOTATATE
PRRT in patients of metastatic/advanced NETs in a large tertiary-care PRRT setting …
PRRT in patients of metastatic/advanced NETs in a large tertiary-care PRRT setting …
Single centre retrospective review of outcome of 177Lu‐DOTATATE peptide receptor radionuclide therapy in the treatment of progressive metastatic neuroendocrine …
S Alsadik, G Gnanasegaran, L Chen… - Journal of …, 2022 - Wiley Online Library
The aim of this study was to evaluate the efficacy and safety of 177Lu‐DOTATATE therapy in
advanced metastatic disease. A retrospective analysis of 395 patients (180 female, 215 …
advanced metastatic disease. A retrospective analysis of 395 patients (180 female, 215 …
[HTML][HTML] Safety and therapeutic optimization of Lutetium-177 based radiopharmaceuticals
T Ladrière, J Faudemer, E Levigoureux, D Peyronnet… - Pharmaceutics, 2023 - mdpi.com
Peptide receptor radionuclide therapy (PRRT) using Lutetium-177 (177Lu) based
radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine …
radiopharmaceuticals has emerged as a therapeutic area in the field of nuclear medicine …
[HTML][HTML] PRRT: identikit of the perfect patient
M Albertelli, A Dotto, C Di Dato, P Malandrino… - Reviews in Endocrine …, 2021 - Springer
Peptide receptor radionuclide therapy (PRRT) has been strengthened since the publication
of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated …
of NETTER-1. Nevertheless, the correct positioning in the therapeutic algorithm is debated …